Remove 2025 Remove Diabetes Remove Manufacturing Remove Patients
article thumbnail

Degree of Weight Loss Affects Tirzepatide-Linked Cardiometabolic Risk Improvement

Physician's Weekly

TUESDAY, July 1, 2025 (HealthDay News) — For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction, according to a study published online June 24 in the Annals of Internal Medicine. Bruno Linetzky, M.D., Bruno Linetzky, M.D.,

article thumbnail

American Diabetes Association, June 20-23

Physician's Weekly

The annual meeting of the American Diabetes Association was held this year from June 20 to 23 in Chicago, drawing more than 15,000 participants, including clinicians, academicians, allied health professionals, and others interested in diabetes. ” The study was funded by MannKind, the manufacturer of Afrezza. .